Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-06-03
Target enrollment:
Participant gender:
Summary
This phase I trial finds the best dose and side effects of cabozantinib and pamiparib in
treating patients with solid tumors that have spread to other places in the body (advanced)
or does not respond to treatment (refractory). Cabozantinib and pamiparib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth.